Date: 2018-09-11
Type of information: Construction of new premises
Compound: new testing capabilities at Lincolnshire facility
Company: SGS (Switzerland)
Therapeutic area: Technology - Services
Type agreement: construction of new premises
Action mechanism:
Disease:
Details:
- • On September 11, 2018, SGS, a leading biopharmaceutical analytical and bioanalytical contract solutions provider, announced that it is investing over $1.7 million to expand its North American biopharmaceutical testing capabilities at its Lincolnshire facility in the northern suburbs of Chicago, Illinois, USA. Installation of all equipment will be completed in Q1 2019.
- The investment, both in expertise and equipment, will extend the biopharmaceutical testing services offered by SGS's current US and Canadian Life Science facilities. Using state-of-the-art methodologies and instrumentation, the new services will focus on quality control analysis and stability testing of biopharmaceuticals.
- The site currently offers a wide range of analytical services, and has adapted 313 cubic meters of stability storage to meet the lower temperature regulatory requirements for peptides and proteins. This additional investment will allow SGS to offer greater capacity for GMP biologics testing capabilities in North America to better serve its biopharmaceutical clients.
- This new development is part of a wider program of investments in the company's global laboratory network. In August 2017, SGS announced a 50% expansion of its Lincolnshire laboratory, growing its footprint to nearly 58,000 sq. ft. Increases in extractables and leachables capabilities have also taken place at Fairfield, New Jersey, and Shanghai, China; while French facilities at Poitiers and Villeneuve-la-Garenne have seen investment in bioanalytical capabilities and elemental analysis respectively.
Financial terms:
Latest news:
Is general: Yes
